Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model Publication Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro-In Vivo Extrapolation Model The pharmacokinetics (PK) of efavirenz (EFV) is characterized by marked inter-patient variability that correlates with…CertaraOctober 1, 2012
Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients Publication Pharmacokinetics and Pharmacodynamics of TBR-652, a Novel CCR5 Antagonist, in HIV-1-Infected, Antiretroviral Treatment-experienced and CCR5 Antagonist-naive Patients TBR-652 is a novel CCR5 antagonist with potent in vitro anti-HIV activity. The objective of…CertaraApril 12, 2011
Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Publication Combining Drug-disease and Economic Modeling to Inform Drug Development Decisions Drug-disease models and clinical trial simulations are increasingly being used to support trial design and…CertaraNovember 1, 2001